肺癌与肿瘤炎症微环境相关性的研究进展
Research Progress on the Correlation between Lung Cancer and Tumor Inflammatory Microenvironment
DOI: 10.12677/jcpm.2024.32050, PDF,   
作者: 彭含含：青海大学临床医学院，青海 西宁；骆玉霜*：青海大学附属医院肿瘤科，青海 西宁
关键词: 肺癌；肿瘤微环境；炎症；Lung Cancer； Tumor Microenvironment； Inflammatory
摘要: 肺癌是临床常见恶性肿瘤之一，其发病率及死亡率居各类恶性肿瘤之首。肿瘤微环境(Tumor Mircroenvirment, TME)与肺癌的发生发展密切相关，而炎症微环境在其中起着重要作用。肿瘤炎症微环境中的炎症细胞和炎症因子通过促进免疫逃逸、肿瘤血管生成、上皮–间充质转化、凋亡等机制，促进肺癌的发生、发展和转移。临床和流行病学研究也显示，慢性感染、炎症、炎症微环境和肺癌之间有着密切的关系。通过对肿瘤炎症微环境的了解，可以更好地解释炎症与肺癌之间的关系，这有利于找到更多的肺癌治疗靶点。
Abstract: Lung cancer is one of the common clinical malignant tumors, and its incidence rate and mortality rate rank the first among all kinds of malignant tumors. Tumor microenvironment (TME) is closely related to the occurrence and development of lung cancer, and the inflammatory microenvironment plays an important role in it. Inflammatory cells and inflammatory factors in the tumor inflammatory microenvironment promote the occurrence, development and metastasis of lung cancer by promoting immune escape, tumor angiogenesis, epithelial-mesenchymal transition, and apoptosis. Clinical and epidemiological studies have also shown a close relationship between chronic infection, inflammation, the inflammatory microenvironment, and lung cancer. The relationship between inflammation can be better explained with lung cancer, which facilitates finding more therapeutic targets for lung cancer.
文章引用：彭含含, 骆玉霜. 肺癌与肿瘤炎症微环境相关性的研究进展[J]. 临床个性化医学, 2024, 3(2): 341-346. https://doi.org/10.12677/jcpm.2024.32050

参考文献

[1] Leiter, A., Veluswamy, R.R. and Wisnivesky, J.P. (2023) The Global Burden of Lung Cancer: Current Status and Future Trends. Nature Reviews Clinical Oncology, 20, 624-639. [Google Scholar] [CrossRef] [PubMed]
[2] Wang, Q., Gümüş, Z.H., Colarossi, C., Memeo, L., Wang, X., Kong, C.Y. and Boffetta, P. (2023) SCLC: Epidemiology, Risk Factors, Genetic Susceptibility, Molecular Pathology, Screening, and Early Detection. Journal of Thoracic Oncology, 18, 31-46. [Google Scholar] [CrossRef] [PubMed]
[3] Balkwill, F. and Mantovani, A. (2001) Inflammation and Cancer: Back to Virchow? The Lancet, 357, 539-545. [Google Scholar] [CrossRef] [PubMed]
[4] Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of Cancer: The Next Generation. Cell, 144, 646-674. [Google Scholar] [CrossRef] [PubMed]
[5] Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y. and Li, Y. (2021) Inflammation and Tumor Progression: Signaling Pathways and Targeted Intervention. Signal Transduction and Targeted Therapy, 6, Article No. 263. [Google Scholar] [CrossRef] [PubMed]
[6] 魏智民, 孙玉发, 李刚, 等. 癌症相关性炎症与肿瘤微环境相关研究进展[J]. 中国肿瘤临床, 2018, 45(21): 1117-1121.
[7] de Visser, K.E. and Joyce, J.A. (2023) The Evolving Tumor Microenvironment: From Cancer Initiation to Metastatic Outgrowth. Cancer Cell, 41, 374-403. [Google Scholar] [CrossRef] [PubMed]
[8] Arneth, B. (2019) Tumor Microenvironment. Medicina, 56, Article 15. [Google Scholar] [CrossRef] [PubMed]
[9] Nagarsheth, N., Wicha, M.S. and Zou, W. (2017) Chemokines in the Cancer Microenvironment and Their Relevance in Cancer Immunotherapy. Nature Reviews Immunology, 17, 559-572. [Google Scholar] [CrossRef] [PubMed]
[10] Bremnes, R.M., Al-Shibli, K., Donnem, T., Sirera, R., Al-Saad, S., Andersen, S., Stenvold, H., Camps, C. and Busund, L. (2011) The Role of Tumor-Infiltrating Immune Cells and Chronic Inflammation at the Tumor Site on Cancer Development, Progression, and Prognosis: Emphasis on Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 6, 824-833. [Google Scholar] [CrossRef] [PubMed]
[11] Brenner, D.R., McLaughlin, J.R. and Hung, R.J. (2011) Previous Lung Diseases and Lung Cancer Risk: A Systematic Review and Meta-Analysis. PLOS ONE, 6, e17479. [Google Scholar] [CrossRef] [PubMed]
[12] Azad, N., Rojanasakul, Y. and Vallyathan, V. (2008) Inflammation and Lung Cancer: Roles of Reactive Oxygen/Nitrogen Species. Journal of Toxicology and Environmental Health, Part B, 11, 1-15. [Google Scholar] [CrossRef] [PubMed]
[13] Zhang, J. and Veeramachaneni, N. (2022) Targeting Interleukin-1β and Inflammation in Lung Cancer. Biomarker Research, 10, Article No. 5. [Google Scholar] [CrossRef] [PubMed]
[14] Que, H., Fu, Q., Lan, T., Tian, X. and Wei, X. (2022) Tumor-Associated Neutrophils and Neutrophil-Targeted Cancer Therapies. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 1877, Article 188762. [Google Scholar] [CrossRef] [PubMed]
[15] Lord, E.M., Penney, D.P., Sutherland, R.M. and Cooper, R.A. (1979) Morphological and Functional Characteristics of Cells Infiltrating and Destroying Tumor Multicellular Spheroids in Vivo. Virchows Archiv B Cell Pathology, 31, 103-116. [Google Scholar] [CrossRef] [PubMed]
[16] 彭译漫, 罗香梦, 陈婧瑶. 肿瘤微环境代谢的研究进展及免疫治疗新策略[J]. 四川大学学报(医学版), 2023, 54(3): 505-509.
[17] Kitamura, T., Qian, B. and Pollard, J.W. (2015) Immune Cell Promotion of Metastasis. Nature Reviews Immunology, 15, 73-86. [Google Scholar] [CrossRef] [PubMed]
[18] Heinrich, E.L., Walser, T.C., Krysan, K., Liclican, E.L., Grant, J.L., Rodriguez, N.L. and Dubinett, S.M. (2011) The Inflammatory Tumor Microenvironment, Epithelial Mesenchymal Transition and Lung Carcinogenesis. Cancer Microenvironment, 5, 5-18. [Google Scholar] [CrossRef] [PubMed]
[19] Semenza, G.L. (2009) Defining the Role of Hypoxia-Inducible Factor 1 in Cancer Biology and Therapeutics. Oncogene, 29, 625-634. [Google Scholar] [CrossRef] [PubMed]
[20] Yoo, Y., Christensen, J. and Huang, L.E. (2011) HIF-1α Confers Aggressive Malignant Traits on Human Tumor Cells Independent of Its Canonical Transcriptional Function. Cancer Research, 71, 1244-1252. [Google Scholar] [CrossRef] [PubMed]
[21] Gomes, M., Teixeira, A.L., Coelho, A., et al. (2014) The Role of Inflammation in Lung Cancer. Advances in Experimental Medicine and Biology, 816, 1-23.
[22] Greten, F.R. and Grivennikov, S.I. (2019) Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity, 51, 27-41. [Google Scholar] [CrossRef] [PubMed]
[23] Mantovani, A., Sozzani, S., Locati, M., Allavena, P. and Sica, A. (2002) Macrophage Polarization: Tumor-Associated Macrophages as a Paradigm for Polarized M2 Mononuclear Phagocytes. Trends in Immunology, 23, 549-555. [Google Scholar] [CrossRef] [PubMed]
[24] Denk, D. and Greten, F.R. (2022) Inflammation: The Incubator of the Tumor Microenvironment. Trends in Cancer, 8, 901-914. [Google Scholar] [CrossRef] [PubMed]
[25] Bent, R., Moll, L., Grabbe, S. and Bros, M. (2018) Interleukin-1 Beta—A Friend or Foe in Malignancies? International Journal of Molecular Sciences, 19, Article 2155. [Google Scholar] [CrossRef] [PubMed]
[26] Greten, F.R., Eckmann, L., Greten, T.F., Park, J.M., Li, Z., Egan, L.J., Kagnoff, M.F. and Karin, M. (2004) IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer. Cell, 118, 285-296. [Google Scholar] [CrossRef] [PubMed]
[27] Saito, A., Horie, M. and Nagase, T. (2018) TGF-β Signaling in Lung Health and Disease. International Journal of Molecular Sciences, 19, Article 2460. [Google Scholar] [CrossRef] [PubMed]
[28] Feng, X. and Derynck, R. (2005) Specificity and Versatility in TGF-β Signaling through Smads. Annual Review of Cell and Developmental Biology, 21, 659-693. [Google Scholar] [CrossRef] [PubMed]
[29] Hao, Y., Baker, D. and ten Dijke, P. (2019) TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis. International Journal of Molecular Sciences, 20, Article 2767. [Google Scholar] [CrossRef] [PubMed]
[30] Gettinger, S., Horn, L., Jackman, D., Spigel, D., Antonia, S., Hellmann, M., Powderly, J., Heist, R., Sequist, L.V., Smith, D.C., Leming, P., Geese, W.J., Yoon, D., Li, A. and Brahmer, J. (2018) Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results from the CA209-003 Study. Journal of Clinical Oncology, 36, 1675-1684. [Google Scholar] [CrossRef] [PubMed]
[31] Choi, Y.L., Soda, M., Yamashita, Y., Ueno, T., Takashima, J., Nakajima, T., Yatabe, Y., Takeuchi, K., Hamada, T., Haruta, H., Ishikawa, Y., Kimura, H., Mitsudomi, T., Tanio, Y. and Mano, H. (2010) EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors. New England Journal of Medicine, 363, 1734-1739. [Google Scholar] [CrossRef] [PubMed]
[32] Blumenschein, G.R. (2011) Developmental Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer (NSCLC). Investigational New Drugs, 30, 1802-1811. [Google Scholar] [CrossRef] [PubMed]
[33] Smith, C.J., Perfetti, T.A. and King, J.A. (2006) Perspectives on Pulmonary Inflammation and Lung Cancer Risk in Cigarette Smokers. Inhalation Toxicology, 18, 667-677. [Google Scholar] [CrossRef] [PubMed]